Literature DB >> 8446919

MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists.

E D French1, A Mura, T Wang.   

Abstract

Extracellular single-unit recordings were used to assess the effects of PCP and PCP-like drugs (MK-801 and TCP) on the burst firing of ventral tegmental A10 dopamine neurons in the rat. The effects of these noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists were compared to the potent and competitive NMDA antagonists CGS 19755 and (+/-)CPP, and to BTCP, a PCP-derivative possessing little affinity for the PCP binding site within the ion channel gated by NMDA. PCP, MK-801, and TCP produced dose-dependent increases in the firing rate, which were accompanied by increases in the amount of burst activity, the number of action potentials within a burst, and the conversion of nonbursty cells to bursty. However, the coefficient of variation, a measure of the regularity of firing, was not significantly altered. These predominately excitatory effects contrast with the inhibition of firing, decrease in bursting, and regularization of pattern produced by BTCP. CGS 197555 and (+/-)CPP failed to alter any of the measured parameters. Thus, the increase in firing rate and amount of burst activity of dopamine neurons produced by PCP and PCP-like drugs, and the resultant hyperdopaminergia within the mesolimbic-mesocortical regions, could underlie the psychotomimetic properties of these compounds. Moreover, this effect would not appear to be related to a loss of activity at the NMDA recognition site, as evidenced by the lack of effect of the competitive NMDA antagonists.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8446919     DOI: 10.1002/syn.890130203

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  14 in total

1.  Disruption of dopamine neuron activity pattern regulation through selective expression of a human KCNN3 mutation.

Authors:  Marta E Soden; Graham L Jones; Christina A Sanford; Amanda S Chung; Ali D Güler; Charles Chavkin; Rafael Luján; Larry S Zweifel
Journal:  Neuron       Date:  2013-10-24       Impact factor: 17.173

2.  The impact of a competitive and a non-competitive NMDA receptor antagonist on dopaminergic neurotransmission in the rat ventral tegmental area and substantia nigra.

Authors:  K Wedzony; A Czyrak; M Maćkowiak; K Fijał
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-04       Impact factor: 3.000

3.  Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia.

Authors:  Maximilian Tufvesson-Alm; Lilly Schwieler; Robert Schwarcz; Michel Goiny; Sophie Erhardt; Göran Engberg
Journal:  Neuropharmacology       Date:  2018-06-05       Impact factor: 5.250

4.  Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice.

Authors:  Sara K Olsson; Markus K Larsson; Sophie Erhardt
Journal:  J Neural Transm (Vienna)       Date:  2011-09-09       Impact factor: 3.575

5.  Engineered D2R Variants Reveal the Balanced and Biased Contributions of G-Protein and β-Arrestin to Dopamine-Dependent Functions.

Authors:  Samuel J Rose; Thomas F Pack; Sean M Peterson; Kaitlin Payne; Emiliana Borrelli; Marc G Caron
Journal:  Neuropsychopharmacology       Date:  2017-10-25       Impact factor: 7.853

6.  Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls.

Authors:  Maria Holtze; Peter Saetre; Göran Engberg; Lilly Schwieler; Thomas Werge; Ole A Andreassen; Håkan Hall; Lars Terenius; Ingrid Agartz; Erik G Jönsson; Martin Schalling; Sophie Erhardt
Journal:  J Psychiatry Neurosci       Date:  2012-01       Impact factor: 6.186

7.  Ibogaine and the dopaminergic response to nicotine.

Authors:  I M Maisonneuve; G L Mann; C R Deibel; S D Glick
Journal:  Psychopharmacology (Berl)       Date:  1997-02       Impact factor: 4.530

8.  Reduction in Ventral Midbrain NMDA Receptors Reveals Two Opposite Modulatory Roles for Glutamate on Reward.

Authors:  Giovanni Hernandez; Ali Khodami-Pour; Daniel Lévesque; Pierre-Paul Rompré
Journal:  Neuropsychopharmacology       Date:  2015-01-12       Impact factor: 7.853

Review 9.  Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

Authors:  Sophie Erhardt; Sara K Olsson; Göran Engberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  Acute and subchronic PCP attenuate D2 autoreceptor signaling in substantia nigra dopamine neurons.

Authors:  Elisabeth Piccart; Christopher W Tschumi; Michael J Beckstead
Journal:  Eur Neuropsychopharmacol       Date:  2019-01-25       Impact factor: 4.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.